Insilico Medicine

What it is

Insilico Medicine is a privately held, AI-first drug-discovery company that uses generative chemistry and target-discovery ML models to identify novel small molecules across age-related disease areas including fibrosis, oncology, and immunological indications.

Programmes

• INS018_055 — a TNIK inhibitor for idiopathic pulmonary fibrosis, one of the first “AI-discovered, AI-designed” small molecules to enter Phase 2 clinical trials.
• Multiple pre-clinical candidates across cardiometabolic, oncology, and age-related disease indications.

Why it’s in a longevity reference

Many of Insilico’s targets are age-related diseases (fibrosis, certain cancers, kidney disease). The company also publishes aging-biology research, including biological-age clocks. The intersection of AI drug discovery and geroscience is a meaningful trend.

What to watch

• Whether INS018_055 reads out positively in Phase 2 fibrosis trials.
• Time-to-clinic for AI-discovered candidates as a benchmark for AI-pharma productivity claims.
• Cross-pollination between aging biology and AI drug discovery.

Related entries

Chronic inflammation, Geroscience hypothesis.